

RAIA DROGASIL S.A.

CNPJ/ME nº 61.585.865/0001-51

NIRE nº 35.300.035.844

Publicly Held Company – Category A

**MATERIAL FACT
SALE OF 4BIO MEDICAMENTOS S.A.**

RAIA DROGASIL S.A. (“RD Saúde”), pursuant to the provisions of article 157, §4, of Law No. 6,404/1976 (“Lei das S.A.”) and Resolution No. 44/2021 of the Brazilian Securities and Exchange Commission (“CVM”), informs that on this date it entered into a Contract with Health Ventures S.A., a company of the Profarma Group, for the sale of 100% of the capital of 4Bio Medicamentos S.A. (“4Bio”), a subsidiary of RD Saúde.

Founded in 2004 and with its control acquired by RD Saúde in 2015, 4Bio operates in specialty retailing, supplying high complexity drugs for patients, health professionals, clinics, hospitals and health operators.

The base value of the transaction amounts to R\$ 600 million, including the maintenance of a net cash position at closing of R\$ 80 million, in addition to other working capital and net debt adjustments that are customary in this type of transaction. The payments will be made in 6 installments as follows: (i) R\$ 100 million at the signing of the deal; (ii) 5 annual installments of R\$ 100 million adjusted by the CDI rate.

Additionally, RD Saúde retains the right to superveniences, including R\$ 120 million related to sales tax rates differential (Difal), which already has a favorable ruling from the Supreme Federal Court. Monetization is expected to occur through the release of judicial deposits, following the final and unappealable court decision. Finally, the transaction will generate an estimated R\$ 60 million corporate income tax gain for RD Saúde.

RD Saúde acquired 4Bio in 2015. Over the last 11 years under its management, 4Bio increased its revenue from R\$ 125 million to R\$ 3.4 billion in the 3Q25 LTM, reaching an adjusted EBITDA IFRS-16 of R\$ 85 million and becoming the leader in specialty medicine, especially in the supplemental health segment. Notwithstanding, 4Bio no longer fits RD Saúde’s strategy, sharpening our focus on the core pharmaceutical retail activity. Additionally, the specialty pharmacy segment has also undergone significant changes in recent years, with current commercial dynamics, margin levels, and return profile more in line with pharmaceutical distribution than with retail. In this context, RD Saúde believes it is no longer the natural owner of the asset.

The sale of 4Bio to the Profarma Group also reinforces RD Saúde’s capital allocation discipline by strengthening its capital structure, reducing net financial expenses and increasing its profitability and ROIC.

The conclusion of the transaction is subject to the approval by the buyer’s shareholders, under the terms of article 256 of Law No. 6,404/76, to the approval by the Brazilian antitrust body (CADE) and to the fulfillment of precedent conditions. The Company will keep the market informed on the subject under the terms of CVM regulations and applicable legislation.

São Paulo, March 03 of 2026

RAIA DROGASIL S.A.

Flávio de Moraes Correia

Investor Relations Director